Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 28, 2026

Wegovy Priority Approval Puts Novo Nordisk Valuation And Risks In Focus

View original at finance.yahoo.com

Wegovy Priority Approval Puts Novo Nordisk Valuation And Risks In Focus Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

One flagged risk is a high level of non cash earnings, so investors may want to look beyond headline profit and focus on cash flow durability as Wegovy scales
60% confidence
Novo Nordisk stock price sits about 26% below analyst consensus target
60% confidence
Novo Nordisk shares are flagged as undervalued, trading around 66.4% below one estimate of fair value
60% confidence

Data points we hold from this source

Novo Nordisk · stock price	36.04 USD
Novo Nordisk · analyst price target	48.84 USD